Validating the NIH LDL-C equation for provincial implementation in Alberta

IF 2.5 3区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY Clinical biochemistry Pub Date : 2023-10-21 DOI:10.1016/j.clinbiochem.2023.110678
V. Higgins , L. Garcia , J.L. Gifford , N. Volodko , D.R. Beriault , M.L. Parker , M.P. Estey , D.T. Proctor , O.Z. Ismail
{"title":"Validating the NIH LDL-C equation for provincial implementation in Alberta","authors":"V. Higgins ,&nbsp;L. Garcia ,&nbsp;J.L. Gifford ,&nbsp;N. Volodko ,&nbsp;D.R. Beriault ,&nbsp;M.L. Parker ,&nbsp;M.P. Estey ,&nbsp;D.T. Proctor ,&nbsp;O.Z. Ismail","doi":"10.1016/j.clinbiochem.2023.110678","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>LDL-C, a cardiovascular disease risk assessment biomarker, is commonly calculated using the Friedewald equation. The NIH equation overcomes several limitations of the Friedewald equation. Consistent with the Canadian Society of Clinical Chemists (CSCC) lipid reporting recommendations, we assessed the NIH LDL-C equation in Alberta prior to its provincial implementation.</p></div><div><h3>Methods</h3><p>1-year (01/01/2021–12/31/2021) of lipid results (n = 1,486,584 after data cleaning) were obtained from five analytical instrument groups used across Alberta. Analyses were performed on all data and after separating by age, analytical instrument group, and fasting status. The correlation between Friedewald- and NIH-calculated LDL-C and between Friedewald- and NIH-calculated LDL-C difference and each lipid parameter, was determined. The frequency of unreportable/inaccurate LDL-C results was compared between the two equations. The concordance between the two equations and with non-HDL-C was determined at LDL-C thresholds. Lastly, LDL-C calculated by Friedewald, NIH, and Martin-Hopkins equations was compared to density-gradient ultracentrifugation.</p></div><div><h3>Results</h3><p>Friedewald- and NIH-calculated LDL-C exhibit the strongest correlation when triglycerides ≤ 4.52 mmol/L. The difference between Friedewald- and NIH-calculated LDL-C increases with decreasing LDL-C concentration. The NIH equation yields fewer inaccurate results (0.35 % vs. 22.0 %). The percent agreement between equations was &gt; 96 % at all LDL-C thresholds, suggesting most patients will not require treatment changes. NIH-calculated LDL-C exhibited better agreement with non-HDL-C when triglycerides ≤ 9.04 mmol/L and better correlated with LDL-C measured by ultracentrifugation (r<sup>2</sup> = 0.926 vs. 0.775 (Friedewald) and 0.863 (Martin-Hopkins)). Results were consistent across age, analytical instrument group, and fasting status.</p></div><div><h3>Conclusions</h3><p>Our findings demonstrate the benefits of implementing the NIH equation across Alberta.</p></div>","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical biochemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0009912023002060","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

LDL-C, a cardiovascular disease risk assessment biomarker, is commonly calculated using the Friedewald equation. The NIH equation overcomes several limitations of the Friedewald equation. Consistent with the Canadian Society of Clinical Chemists (CSCC) lipid reporting recommendations, we assessed the NIH LDL-C equation in Alberta prior to its provincial implementation.

Methods

1-year (01/01/2021–12/31/2021) of lipid results (n = 1,486,584 after data cleaning) were obtained from five analytical instrument groups used across Alberta. Analyses were performed on all data and after separating by age, analytical instrument group, and fasting status. The correlation between Friedewald- and NIH-calculated LDL-C and between Friedewald- and NIH-calculated LDL-C difference and each lipid parameter, was determined. The frequency of unreportable/inaccurate LDL-C results was compared between the two equations. The concordance between the two equations and with non-HDL-C was determined at LDL-C thresholds. Lastly, LDL-C calculated by Friedewald, NIH, and Martin-Hopkins equations was compared to density-gradient ultracentrifugation.

Results

Friedewald- and NIH-calculated LDL-C exhibit the strongest correlation when triglycerides ≤ 4.52 mmol/L. The difference between Friedewald- and NIH-calculated LDL-C increases with decreasing LDL-C concentration. The NIH equation yields fewer inaccurate results (0.35 % vs. 22.0 %). The percent agreement between equations was > 96 % at all LDL-C thresholds, suggesting most patients will not require treatment changes. NIH-calculated LDL-C exhibited better agreement with non-HDL-C when triglycerides ≤ 9.04 mmol/L and better correlated with LDL-C measured by ultracentrifugation (r2 = 0.926 vs. 0.775 (Friedewald) and 0.863 (Martin-Hopkins)). Results were consistent across age, analytical instrument group, and fasting status.

Conclusions

Our findings demonstrate the benefits of implementing the NIH equation across Alberta.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
验证NIH LDL-C方程在艾伯塔省的省级实施。
背景:LDL-C是一种心血管疾病风险评估生物标志物,通常使用弗里德瓦尔德方程计算。NIH方程克服了Friedewald方程的几个局限性。根据加拿大临床化学家协会(CSCC)的脂质报告建议,我们在艾伯塔省实施NIH LDL-C方程之前对其进行了评估。方法:从阿尔伯塔省使用的五个分析仪器组中获得一年(2021年1月1日至2021年12月31日)的脂质结果(数据清理后n=1486584)。根据年龄、分析仪器组和禁食状态对所有数据进行分析。测定Friedewald和NIH计算的LDL-C之间的相关性,以及Friedewald与NIH计算LDL-C差异与每个脂质参数之间的相关性。比较了两个方程之间LDL-C结果不可重复/不准确的频率。在LDL-C阈值下确定两个方程和非HDL-C之间的一致性。最后,将Friedewald、NIH和Martin Hopkins方程计算的LDL-C与密度梯度超速离心进行比较。结果:当甘油三酯≤4.52mmol/L时,Friedewald和NIH计算的LDL-C表现出最强的相关性。Friedewald与NIH计算LDL-C之间的差异随着LDL-C浓度的降低而增加。NIH方程产生的不准确结果较少(0.35%对22.0%)。在所有LDL-C阈值下,方程之间的一致性百分比>96%,这表明大多数患者不需要改变治疗。当甘油三酯≤9.04mmol/L时,NIH计算的LDL-C与非HDL-C表现出更好的一致性,并且与通过超速离心测量的LDL-C更好地相关(r2=0.926对0.775(Friedewald)和0.863(Martin Hopkins))。不同年龄、分析仪器组和禁食状态的结果一致。结论:我们的研究结果证明了在阿尔伯塔省实施NIH方程的好处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical biochemistry
Clinical biochemistry 医学-医学实验技术
CiteScore
5.10
自引率
0.00%
发文量
151
审稿时长
25 days
期刊介绍: Clinical Biochemistry publishes articles relating to clinical chemistry, molecular biology and genetics, therapeutic drug monitoring and toxicology, laboratory immunology and laboratory medicine in general, with the focus on analytical and clinical investigation of laboratory tests in humans used for diagnosis, prognosis, treatment and therapy, and monitoring of disease.
期刊最新文献
Challenges and Perspectives on the Adoption of Cystatin C testing in China: A laboratory technician’s perspective Quantitative evaluation of adalimumab and anti-adalimumab antibodies in sera using a surface plasmon resonance biosensor Inflammation and lipoperoxidation in mucopolysaccharidoses type II patients at diagnosis and post-hematopoietic stem cell transplantation. Multidisciplinary approach to redefining thyroid hormone reference intervals with big data analysis Relationship between analytical imprecision and coefficient of determination (R2) of the calibration curve
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1